Introduction {#Sec1}
============

Phototherapy, or light therapy, involves regularly exposing the skin to specific wavelengths of ultraviolet (UV) light under medical supervision to treat various skin conditions. The UV light spectrum is divided into UVC (200--280 nm), UVB (280--320 nm), and UVA (320--400 nm). UVB is further subdivided into broadband (280--320 nm) and narrowband (311--313 nm) portions \[[@CR1]\].

Dermatologists began utilizing broadband UVB (BB--UVB) for the treatment of psoriasis in the late 1970s. In the following two decades, they discovered that narrowband UVB (NB-UVB) was potentially safer and more effective, with faster skin clearance and longer-lasting remission. Furthermore, it is thought that NB-UVB encompasses "therapeutic" wavelengths that are distinct from "burning" wavelengths in the UVB spectrum \[[@CR2]\]. NB-UVB subsequently replaced BB-UVB as a first-line treatment for psoriasis \[[@CR3]--[@CR7]\].

Common indications for NB-UVB phototherapy include psoriasis, atopic dermatitis, and vitiligo \[[@CR1], [@CR8]\]. Although BB-UVB is now rarely used for psoriasis, it can be effectively used for atopic dermatitis and generalized pruritus. Moreover, some patients who respond inadequately to NB-UVB may benefit from a trial of BB-UVB.

Typically, patients with moderate-to-severe psoriasis require 20--36 sessions of NB-UVB phototherapy at a frequency of three sessions per week to see a significant improvement in their skin \[[@CR9]\]. Each phototherapy appointment usually lasts about 15 min, although some patients may require up to 30 min, if more time preparing for phototherapy is needed. A minimum of 24 h is required between each session. Additionally, physician follow-up is required every 3 months for the first year of treatment and then every 6 months thereafter. At the end of the initial phase of therapy, clearance rates are often reported to be in the 60--70% range, which is comparable to many of the systemic agents available for the treatment of moderate-to-severe psoriasis today \[[@CR4], [@CR10], [@CR11]\]. After skin clearing, the frequency of phototherapy is gradually reduced to once weekly for long-term maintenance.

Initial dosing of phototherapy at the University of California--San Francisco (UCSF) Psoriasis and Skin Treatment Center is based on a patient's Fitzpatrick skin type, for instance with skin type I starting at 130 mJ and skin type VI starting at 400 mJ. If a patient is on a concomitant photosensitizing drug at the start of treatment, the initial dose is shifted down one level to that of the preceding Fitzpatrick skin type. As treatment progresses, small incremental increases in dose are introduced as tolerated to minimize skin toxicity and total UVB exposure. The treatment goal is to maintain a mild amount of erythema for optimal results \[[@CR12]\].

If a patient does not receive UVB phototherapy for a period of 12--20 days, the dose is decreased by at least 25% to prevent skin from burning. A 21- to 27-day break requires a 50% reduction in dose. Finally, 28 or more days off requires the patient to start the regimen again.

Patients are encouraged to consistently use topical medications as prescribed in conjunction with phototherapy to achieve the best results. This may include topical corticosteroids, topical vitamin D analogs, or topical retinoids \[[@CR13]--[@CR16]\]. Patients taking acitretin, an oral retinoid, may continue to do so; however, it is recommended that the initial phototherapy dose may be decreased by 25%. Biologic agents can be successfully combined with phototherapy for enhanced efficacy. Other systemic agents such as cyclosporine and methotrexate are not typically used in conjunction with phototherapy \[[@CR17]\] due to a possible increased risk of skin cancer or phototoxicity, respectively \[[@CR18]\].

Below, we will describe the safety considerations, flow of treatment, appropriate skin care, and possible side effects of UVB phototherapy.

Methods {#Sec2}
=======

We reviewed the UVB phototherapy treatment protocol used at the UCSF Psoriasis and Skin Treatment Center. We also performed a PUBMED search using "ultraviolet B" or "UVB" AND "phototherapy" to identify relevant articles to design a comprehensive guide for patients receiving UVB treatment.

This article does not involve any new studies of human or animal subjects performed by any of the authors. All photos are printed with the consent of the subject(s).

Results and Discussion {#Sec3}
======================

Overview {#Sec4}
--------

Each UVB phototherapy session involves the patient as well as a care team of nurses, supporting staff, and/or doctors (Table [1](#Tab1){ref-type="table"}). The phototherapy is delivered in a light box with adjustable energy settings, a fan, and a timer that are all controlled by a nurse. Although the light administration itself is often very brief (ranging from several seconds to a few minutes), much of the appointment consists of before-and-after precautions taken to ensure patient safety while maximizing treatment efficacy. Therefore, each appointment generally lasts about 15 min, although some patients may require up to 30 min, if more time preparing for light therapy is needed.Table 1Overview of ultraviolet B phototherapyTypically requires 20--36 sessions\
3 sessions per week\
Appointments last between 15 and 30 min\
Minimum 24-h interval between each session\
Physician follow-up every 3 months for the first year\
Physician follow-up every 6 months after the first year\
Clearance rates range from 60 to 70%

Safety Precautions {#Sec5}
------------------

Patients must bring a list of all current medications, including herbs and supplements, to the first appointment for review with the phototherapy nurse (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). In general, patients should notify the nurse of any medication changes as they arise. For each session of phototherapy, patients must have bare skin that is free of lotions and perfumes or colognes, as these may make skin more sensitive to light. Eye protection with UVB-filtering goggles provided in the clinic is required unless there are periorbital lesions (skin involvement around the eyes) that may benefit from UVB light. In that case, closing the eyelids during irradiation will suffice, as it has been shown that UV light does not penetrate the eyelids \[[@CR19]\]. A towel is also generally wrapped around the face if the skin condition is not present there. Finally, genital coverage is required of all male patients unless an exception has been approved by a physician. NB-UVB is also safe for use in pregnancy \[[@CR20], [@CR21]\].Table 2Safety precautions for ultraviolet B phototherapyDisclosure of all current medications, herbs, and supplements\
Bare skin (no skin care products) prior to phototherapy sessions\
Eye protection with clean goggles or close the eyes (Fig. [1](#Fig1){ref-type="fig"})\
Face shielding with towel\
Male genital coverage with cone or towel\
Safe for use in pregnancyFig. 1UVB eye protection

Flow of Treatment {#Sec6}
-----------------

At each session of phototherapy, the patient checks in at the front desk and proceeds to gather all necessary supplies, which include clean goggles, a hospital gown, towels, and genital coverage for men (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). The phototherapy nurse asks the patient to state his/her full name and date of birth to ensure safety. The patient then changes into a hospital gown in a dressing room. The nurse then examines the patient's skin thoroughly to assess skin response from previous phototherapy treatments, if applicable. This helps the nurse determine if any phototherapy dose adjustment will be required for the session. Next, the patient is asked to step into the UVB box and to assume a position that ensures maximal light penetration to all affected areas. The nurse then adjusts the light settings according to the patient's needs and the session is started. UVB light is administered to the patient's skin for several seconds to minutes, depending on the dose. In some cases, the nurse may cover the patient's face and/or trunk and give additional doses to the arms and legs. This is because the arms and legs can typically withstand higher doses of light without burning, and higher doses of light may be required to treat the affected areas on the arms and legs compared to the face and trunk. In some cases in which the patient has psoriasis lesions on the lower legs, the patient may be asked to stand on a step stool to allow for a greater amount of light to reach the lower legs. After treatment, the patient steps out of the UVB box and returns to the dressing room where the nurse offers to apply lotion to hard-to-reach areas such as the back, and gives the patient extra lotion to moisturize the rest of his/her skin. Following this, the patient can get dressed and the treatment session is complete.Table 3Flow of treatment for UVB phototherapy*UVB* ultraviolet B^a^Genital coverage may be required for male patientsFig. 2Pre-phototherapy skin inspection

Post-Phototherapy Skin Care {#Sec7}
---------------------------

It is important to minimize skin irritation post-phototherapy (Table [4](#Tab4){ref-type="table"}). When bathing, patients should use a mild soap or skin cleanser. Shortening shower times and limiting showers to once per day is helpful. In addition, water temperature should be warm at most, but not hot. It is important for patients to moisturize their skin very thoroughly at least twice daily while receiving phototherapy. The best time to moisturize is immediately after bathing.Table 4Post-phototherapy skin care for ultraviolet B phototherapyBathe with mild soap or cleanser\
Shorten shower times\
Limit to one shower per day\
Use warm (not hot) water only\
Moisturize skin twice daily^aa^Best time to moisturize is immediately after bathing

Side Effects {#Sec8}
------------

Although maintenance of a mild skin erythema is desired for optimal results, burning should be avoided (Table [5](#Tab5){ref-type="table"}). Signs and symptoms of burning post-phototherapy include moderate-to-severe redness, tenderness, pain, tightness, itching, and rarely blistering of skin. Normally, if a burn is secondary to light treatment, it will become noticeable 4--6 h after the phototherapy session. If patients experience any of the signs or symptoms of burning, they should promptly apply a topical steroid to the affected skin in an effort to lessen and arrest the burn. Patients are also encouraged to call their phototherapy clinic for further assistance if needed.Table 5Side effects of UVB phototherapySide effect^a^Signs/symptomsBurningRedness, tenderness, pain, tightness, itching, and rarely blistering\
Noticeable 4--6 h after treatmentPhotoagingCoarseness, wrinkling, laxity, increased fragility, mottled pigmentation, telangiectasias, and atrophic or fibrotic areasTanningSkin darkening*UVB* ultraviolet B^a^Skin cancer is not a side effect of UVB phototherapy

Other possible side effects of phototherapy include photoaging and tanning \[[@CR12]\]. No significant increased risk of skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma, has been seen in association with NB-UVB phototherapy regardless of the patient's skin type \[[@CR7], [@CR22]--[@CR24]\].

Conclusions {#Sec9}
===========

UVB phototherapy is a safe and effective treatment option for patients with psoriasis, eczema, vitiligo, and other photo-responsive disorders. The key to success with phototherapy is consistency. To achieve optimal results, patients must commit to at least 20 sessions of treatment. With the appropriate safety and skin care precautions taken, phototherapy can help patients safely achieve rapid skin clearance and long-lasting remission. We hope this guide will be a valuable resource for patients preparing for UVB phototherapy, the clinicians who treat them, and trainees wishing to learn more about this form of therapy.
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